Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases

被引：1

作者：

Kast, Karin ^{[1
,2
]}

Haefner, Julia ^{[3
,4
,5
,6
,7
]}

Schroeck, Evelin ^{[5
,6
,7
,8
,9
,10
]}

Jahn, Arne ^{[5
,6
,7
,8
,9
,10
]}

Werner, Carmen ^{[11
]}

Meisel, Cornelia ^{[3
,4
,5
,6
,7
]}

Wimberger, Pauline ^{[3
,4
,5
,6
,7
]}

机构：

[1] Univ Hosp Cologne, Ctr Familial Breast & Ovarian Canc, Cologne, Germany

[2] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[3] Tech Univ Dresden, Fac Med, Dept Gynecol & Obstet, Dresden, Germany

[4] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany

[5] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany

[6] German Canc Consortium DKTK, Heidelberg, Germany

[7] German Canc Res Ctr DKFZ Heidelberg, Heidelberg, Germany

[8] Tech Univ Dresden, Fac Med, Inst Clin Genet, Dresden, Germany

[9] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany

[10] Tech Univ Dresden, Hereditary Canc Syndrome Ctr Dresden, Fac Med, Dresden, Germany

[11] Tech Univ Dresden, Reg Clin Canc Registry, Dresden, Germany

来源：

BREAST CARE | 2022年 / 17卷 / 02期

关键词：

Recommendation; Acceptance; Genetic; Counselling; Breast cancer; BRCA1/2 GERMLINE MUTATIONS; HEREDITARY BREAST; OVARIAN-CANCER; GERMAN CONSORTIUM; REDUCING SURGERY; PREVALENCE; CONSENSUS; SUBTYPES; GENES; WOMEN;

D O I：

10.1159/000517021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany. Methods: All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden. Results: Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes BRCA1 or BRCA2. Conclusion: Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.

引用

页码：153 / 158

页数：6

共 26 条

[11] Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer [J].

Kast, Karin ;

Rhiem, Kerstin ;

Wappenschmidt, Barbara ;

Hahnen, Eric ;

Hauke, Jan ;

Bluemcke, Britta ;

Zarghooni, Verena ;

Herold, Natalie ;

Ditsch, Nina ;

Kiechle, Marion ;

Braun, Michael ;

Fischer, Christine ;

Dikow, Nicola ;

Schott, Sarah ;

Rahner, Nils ;

Niederacher, Dieter ;

Fehm, Tanja ;

Gehrig, Andrea ;

Mueller-Reible, Clemens ;

Arnold, Norbert ;

Maass, Nicolai ;

Borck, Guntram ;

de Gregorio, Nikolaus ;

Scholz, Caroline ;

Auber, Bernd ;

Varon-Manteeva, Raymonda ;

Speiser, Dorothee ;

Horvath, Judit ;

Lichey, Nadine ;

Wimberger, Pauline ;

Stark, Sylvia ;

Faust, Ulrike ;

Weber, Bernhard H. F. ;

Emons, Gunter ;

Zachariae, Silke ;

Meindl, Alfons ;

Schmutzler, Rita K. ;

Engel, Christoph .

JOURNAL OF MEDICAL GENETICS, 2016, 53 (07) :465-471

[12] Impact of breast cancer subtypes and patterns of metastasis on outcome [J].

Kast, Karin ;

Link, Theresa ;

Friedrich, Katrin ;

Petzold, Andrea ;

Niedostatek, Antje ;

Schoffer, Olaf ;

Werner, Carmen ;

Klug, Stefanie J. ;

Werner, Andreas ;

Gatzweiler, Axel ;

Richter, Barbara ;

Baretton, Gustavo ;

Wimberger, Pauline .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (03) :621-629

[13] Treatment Decision Making and Genetic Testing for Breast Cancer Mainstreaming Mutations [J].

Katz, Steven J. ;

Kurian, Allison W. ;

Morrow, Monica .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (10) :997-998

[14] Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers [J].

Kuchenbaecker, Karoline B. ;

Hopper, John L. ;

Barnes, Daniel R. ;

Phillips, Kelly-Anne ;

Mooij, Thea M. ;

Roos-Blom, Marie-Jose ;

Jervis, Sarah ;

van Leeuwen, Flora E. ;

Milne, Roger L. ;

Andrieu, Nadine ;

Goldgar, David E. ;

Terry, Mary Beth ;

Rookus, Matti A. ;

Easton, Douglas F. ;

Antoniou, Antonis C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23) :2402-2416

[15] Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer [J].

Kurian, Allison W. ;

Griffith, Kent A. ;

Hamilton, Ann S. ;

Ward, Kevin C. ;

Morrow, Monica ;

Katz, Steven J. ;

Jagsi, Reshma .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (05) :531-534

[16] Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial [J].

Litton, J. K. ;

Hurvitz, S. A. ;

Mina, L. A. ;

Rugo, H. S. ;

Lee, K-H ;

Goncalves, A. ;

Diab, S. ;

Woodward, N. ;

Goodwin, A. ;

Yerushalmi, R. ;

Roch, H. ;

Im, Y-H ;

Eiermann, W. ;

Quek, R. G. W. ;

Usari, T. ;

Lanzalone, S. ;

Czibere, A. ;

Blum, J. L. ;

Martin, M. ;

Ettl, J. .

ANNALS OF ONCOLOGY, 2020, 31 (11) :1526-1535

[17] The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice [J].

Menko, Fred H. ;

ter Stege, Jacqueline A. ;

van der Kolk, Lizet E. ;

Jeanson, Kiki N. ;

Schats, Winnie ;

Moha, Daoud Ait ;

Bleiker, Eveline M. A. .

FAMILIAL CANCER, 2019, 18 (01) :127-135

[18] Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer [J].

Rana, Huma Q. ;

Kipnis, Lindsay ;

Hehir, Kristin ;

Cronin, Angel ;

Jaung, Tim ;

Stokes, Samantha M. ;

Fekrmandi, Fatemeh ;

Vatnick, Donna ;

Matulonis, Ursula A. ;

Garber, Judy E. ;

Wright, Alexi A. .

GYNECOLOGIC ONCOLOGY, 2021, 160 (02) :457-463

[19] Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort [J].

Rhiem, Kerstin ;

Buecker-Nott, Hans-Joachim ;

Hellmich, Martin ;

Fischer, Holger ;

Ataseven, Beyhan ;

Dittmer-Grabowski, Christine ;

Latos, Kunibert ;

Pelzer, Volker ;

Seifert, Manuela ;

Schmidt, Andrea ;

Rezek, Daniela ;

Groh, Ulrich ;

Meinerz, Wolfgang ;

Crommelinck, Dirk ;

Hahnen, Eric ;

Wesselmann, Simone ;

Schmutzler, Rita Katharina .

BREAST JOURNAL, 2019, 25 (03) :455-460

[20] The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study [J].

Rhiem, Kerstin ;

Engel, Christoph ;

Graeser, Monika ;

Zachariae, Silke ;

Kast, Karin ;

Kiechle, Marion ;

Ditsch, Nina ;

Janni, Wolfgang ;

Mundhenke, Christoph ;

Golatta, Michael ;

Varga, Dominic ;

Preisler-Adams, Sabine ;

Heinrich, Tilman ;

Bick, Ulrich ;

Gadzicki, Dorothea ;

Briest, Susanne ;

Meindl, Alfons ;

Schmutzler, Rita K. .

BREAST CANCER RESEARCH, 2012, 14 (06)

← 1 2 3 →